Technology
University of Maryland, Baltimore and University of Maryland, College Park Announce $10 Million Joint Gift from Edward and Jennifer St. John and the Edward St. John Foundation for New Center for Translational Engineering and Medicine
Published
2 years agoon
By
Philanthropic investment to fuel innovation, collaboration and accelerated tech transfer to improve human health in Baltimore and beyond
COLLEGE PARK, Md., Jan. 10, 2025 /PRNewswire/ — The University of Maryland, Baltimore (UMB) and the University of Maryland, College Park (UMCP) are pleased to announce a $10 million joint gift from Edward and Jennifer St. John and the Edward St. John Foundation. This landmark investment will launch the Edward & Jennifer St. John Center for Translational Engineering and Medicine (CTEM), a collaboration between the University of Maryland School of Medicine (UMSOM) at UMB and the A. James Clark School of Engineering at UMCP. Together, researchers from these distinct disciplines will tackle a broad spectrum of generational health challenges and drive medical innovations that benefit patients in Maryland and beyond.
Occupying the fourth floor of 4MLK — a new state-of-the-art facility in the University of Maryland BioPark in Baltimore — the Edward & Jennifer St. John Center for Translational Engineering and Medicine will foster face-to-face collaboration among clinicians and engineers as they develop next-generation medical solutions. Their proximity will ensure that the real-world medical needs of healthcare professionals and patients directly inform the development of devices, diagnostics and treatments, and accelerate the pathway from research to patient care.
“This significant gift allows us to unite the expertise of UMB’s clinicians with the engineering ingenuity of UMCP’s faculty, who together will discover innovative treatments and breakthrough technologies that simply cannot emerge when each works in isolation,” said UMB President Bruce E. Jarrell, MD, FACS. “This synergy opens exciting new possibilities for translating research into tangible solutions that will address today’s most pressing health challenges.”
“This collaboration will be one of the premier partnerships in the country that fully bridges the gap between engineering and medicine to rapidly accelerate solutions on public health, disease and wellness,” said UMCP President Darryll J. Pines, PhD, MS. “Whether it is the invention of new devices and instruments or improved analysis, this center will be leading the way in advancing how clinicians work and how patients heal.”
Edward St. John graduated from UMCP with an engineering degree and went on to become a noted Baltimore-based business leader and philanthropist. He previously gave $10 million to help build the Edward St. John Learning and Teaching Center, a 187,000-square-foot facility that fosters student-centered learning on the College Park campus. This new gift will establish endowed and current-use professorships in bioengineering, undergraduate and graduate student awards in translational engineering and medicine, and ongoing operating funds for the center.
He has long championed UMB’s mission to improve the human condition and serve the public good through research, healthcare innovation and education. Building on his early $1 million gift to support the R Adams Cowley Shock Trauma Center and his ongoing commitment to UMB’s CURE Scholars Program, St. John pledged another $1 million in 2021 to establish a Clinical Stem Cell Laboratory at the University of Maryland Medical Center. This newest contribution underscores his and Jennifer St. John’s enduring dedication to improving lives and fueling scientific progress across the state.
“It is our great pleasure to support this transformational, lifesaving and life-altering work, knowing that our contribution helps pave the way for groundbreaking discoveries that will improve and extend lives for years to come,” said Jennifer St. John.
“The Edward and Jennifer St. John Center for Translational Engineering and Medicine — where diverse minds unite, each contributing their unique expertise, pushing the boundaries of what’s possible in medicine,” added Edward St. John.
Born out of Edward St. John’s commitment to giving back, the Edward St. John Foundation operates on the belief that education has the power to transform lives and provides the foundation for success. Over the years, it has provided financial assistance for educational programs across Maryland and beyond.
Sharon Akers, president of the Edward St. John Foundation, said, “The Edward and Jennifer St. John Center for Translational Engineering and Medicine will provide transformative solutions that will revolutionize healthcare and save lives. It will drive groundbreaking innovation and serve as a platform for recruitment and retention, attracting the best and brightest talent right here to the University of Maryland.”
CTEM is led by Giuliano Scarcelli, PhD, co-director and associate professor in the Fischell Department of Bioengineering in the A. James Clark School of Engineering at UMCP, and Osamah J. Saeedi, MD, clinical co-director and professor of ophthalmology and visual sciences at UMSOM. Their collaborative work using cutting-edge ophthalmologic imaging to address ocular diseases such as glaucoma exemplifies the center’s mission of fostering cross-campus partnerships in the development of interventions that improve patients’ lives.
“Engineers are stewards of technological innovations for the public good, proudly creating and collaborating to improve the human condition. By embedding engineers with doctors, we will improve diagnostics tools, disease treatment and ultimately patient care — helping people live healthier lives,” said Samuel Graham, Jr., PhD, MS, dean of the A. James Clark School of Engineering. “We look forward to the CTEM and its associated educational programs growing the long-standing partnership between the UMSOM and the Clark School’s Fischell Department of Bioengineering, one of the most prestigious bioengineering programs in the country.”
Scarcelli and Saeedi’s trailblazing research in glaucoma illustrates how the center will cultivate new possibilities across bioengineering and medicine. Building on these breakthroughs, the center will expand into diverse areas of translational science, encouraging broader collaborations that accelerate discovery and improve patient outcomes well beyond eye care.
“We are profoundly grateful to Ed and Jennifer St. John for their leadership and commitment to pioneering the next generation of biomedical technology and innovation,” said Mark T. Gladwin, MD, dean of UMSOM. “This new center marks the beginning of a new era in biomedical innovation – a bold vision to break down traditional educational and research silos and create a dynamic ecosystem where engineers and medical professionals work hand-in-hand to solve some of the most pressing health challenges of our time. Imagine a future where biomedical engineers and physician-scientists work together to engineer and rebuild new organs, and use artificial intelligence, wearable devices and robotics to diagnose and treat diseases in the home.”
The 35,000 sq. ft. facility occupies the entire fourth floor of 4MLK and was custom designed by UMSOM to facilitate collaboration between UMB and UMCP researchers. State-of-the-art equipment and easy access to UMB’s core labs and facilities will allow researchers to iterate their ideas as they develop potential new products.
Its location in 4MLK, the most recent addition to UMB’s 14-acre BioPark, places the center at the heart of a thriving biomedical innovation hub that is transforming Baltimore’s biotechnology landscape. By fostering groundbreaking research and cross-disciplinary collaboration, the center will not only advance medical science but also reinforce the critical role of the biotechnology sector in driving economic growth and scientific progress throughout Baltimore and the greater region.
“We are thrilled to have the Edward & Jennifer St. John Center for Translational Engineering and Medicine locate in 4MLK,” commented Jim Hughes, chief enterprise and economic development officer and senior vice president at UMB and president of the BioPark. “In addition to providing cutting-edge facilities for life and health science innovation, one of the BioPark’s core missions is to create connection that further strengthens Baltimore’s thriving life science industry. CTEM researchers will join a vibrant, collaborative community in the BioPark and be well-supported as they advance their innovative health care technologies.”
NOTE TO EDITORS/REPORTERS: Photos, b-roll and additional information will be available here following the ceremony.
ABOUT THE UNIVERSITY OF MARYLAND, BALTIMORE
The University of Maryland, Baltimore (UMB) was founded in 1807 as the Maryland College of Medicine, which now stands as the nation’s oldest public medical school. In response to growing social and cultural needs, UMB’s mission has evolved and grown tremendously. Widely recognized as a preeminent institution, UMB serves as the academic health, law, and social work university of the University System of Maryland, and is guided by a mission of excellence in education, research, clinical care, and public service.
UMB is a thriving academic health center combining cutting-edge biomedical research, exceptional patient care, and nationally ranked academic programs. With extramural funding totaling $682 million in Fiscal Year 2021, each tenured/tenure-track faculty member generates an average of $1.5 million in research grants each year. The 3,123 faculty members conduct leading-edge research and develop solutions and technologies that impact human health locally and around the world. World-class facilities and cores, as well as interprofessional centers and institutes, allow faculty to investigate pressing questions in a highly collaborative fashion. As a result, the more than 7,200 students, postdocs, and trainees directly benefit from working and learning alongside leading experts as they push the boundaries of their fields. For a listing of the organized research centers and institutes, visit: https://www.umaryland.edu/research/umb-research-profile/research-centers-and-institutions/
ABOUT THE UNIVERSITY OF MARYLAND, COLLEGE PARK
The University of Maryland (UMD) is the state’s flagship university and a leading public research institution, propelled by a $1.3 billion joint research enterprise. Located four miles from Washington, D.C., the university is dedicated to addressing the grand challenges of our time and is the nation’s first Do Good campus. It is driven by a diverse and proudly inclusive community of more than 50,000 fearless Terrapins. UMD is a top producer of Fulbright scholars and offers an unparalleled student experience with more than 300 academic programs, 25 living-learning programs and 400 study abroad programs. Spurred by a culture of innovation and creativity, UMD faculty are global leaders in their field and include Nobel laureates, Pulitzer Prize winners and members of the national academies. For more information about the University of Maryland, visit umd.edu.
ABOUT THE EDWARD ST. JOHN FOUNDATION
The Edward St. John Foundation provides financial assistance to formal educational programs with a primary focus on schools and medical institutions. Over the years, more than $65 million has been contributed, pledged and gifted through donations by the Foundation, Edward St. John and St. John Properties to more than 750 organizations. The Foundation is funded through 7.5% of the annual net income of St. John Properties. The mission is based on the belief that the transformative powers of education can change lives and strengthen communities.
View original content to download multimedia:https://www.prnewswire.com/news-releases/university-of-maryland-baltimore-and-university-of-maryland-college-park-announce-10-million-joint-gift-from-edward-and-jennifer-st-john-and-the-edward-st-john-foundation-for-new-center-for-translational-engineering-and-medic-302348091.html
SOURCE University of Maryland
You may like
Technology
Vertical IQ Will Expand Industry Intelligence Platform with Small Business Financial Exchange (SBFE) Small Business Credit Data
Published
13 minutes agoon
October 27, 2026By
RALEIGH, N.C., Oct. 27, 2026 /PRNewswire/ — Small Business Financial Exchange (SBFE), the trusted source for small business lending data and Vertical IQ, a nationally recognized provider of Industry Intelligence, today announced their partnership. Through the partnership, Vertical IQ will incorporate SBFE small business credit insights into its platform, providing financial institutions with deeper context to support commercial lending decisions.
The collaboration enables banks, credit unions, and other commercial lenders using Vertical IQ to gain access to SBFE small business credit insights within the Industry Intelligence platform. Default rates, delinquencies, and credit trends by industries are just a few of the SBFE features that will be included. These insights allow financial services professionals to better understand small business borrowers and support key commercial lending activities.
“At SBFE, we’re committed to helping lenders better understand and support small businesses. Extending access to SBFE insights through Vertical IQ is another way we can deliver value to the lending community and support greater access to capital.”
– Elisabeth MacDonald, President and CEO, SBFE
“At Vertical IQ, we believe financial institutions make their best decisions when they have access to trusted, Verified Industry Intelligence powered by the highest-quality data available,” said Bobby Martin, co-founder and CEO of Vertical IQ. “Our partnership with SBFE represents another important step in that commitment by bringing highly respected small business credit insights into our platform. By combining SBFE’s credit data with Vertical IQ’s industry expertise, we’re helping lenders gain deeper context to strengthen credit analysis, improve risk assessment, and make more confident decisions throughout the commercial lending lifecycle.”
– Bobby Martin, Co-founder and CEO, Vertical IQ
About SBFE
SBFE is the trusted data exchange where the small business lending industry comes together to strengthen access to capital for America’s small businesses. For more than 25 years, SBFE has united lenders in a member-driven community built on trust, collaboration, and the responsible use of data. Today, SBFE securely manages one of the nation’s largest repositories of small business credit data, contributed by more than 140 member institutions, including many of the country’s largest commercial banks. This data enables highly predictive credit reporting and portfolio management solutions that help lenders make more informed decisions, manage risk, and support the financial health and growth of small businesses. By transforming shared data into trusted lending intelligence, SBFE helps its members strengthen credit decisioning and promote greater access to capital. Learn more at www.SBFE.org
About Vertical IQ
Headquartered in Raleigh, North Carolina, Vertical IQ is a nationally recognized provider of Industry Intelligence. Whether discussing cash management with a local brewery or evaluating risk for a large manufacturing company, successful banks, credit unions, accounting firms, insurance organizations, and advisory firms use Vertical IQ to better understand a prospect’s or client’s business challenges before, during, and after meetings. Covering 100% of the industries that comprise the U.S. and Canadian economies, as well as more than 3,400 local economic reports, Vertical IQ equips professionals with the confidence and credibility to build stronger client relationships and make more informed decisions. Learn more at www.verticaliq.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vertical-iq-will-expand-industry-intelligence-platform-with-small-business-financial-exchange-sbfe-small-business-credit-data-302920872.html
SOURCE SBFE
Technology
CME Group Brazilian Real Futures Set New Daily Volume Record Following Election
Published
13 minutes agoon
October 27, 2026By
Record $9 billion notional traded, eleven times the year-to-date average daily volume (ADV) as market participants turned to CME Group to manage risk around the clock
CHICAGO, Oct. 27, 2026 /PRNewswire/ — CME Group, the world’s leading derivatives marketplace, today announced that its Brazilian real (BRL) futures reached a new daily volume record of 498,498 contracts (R$49.8 billion, ~$9.2 billion notional value) on October 26, surpassing the previous record of 191,325 contracts (~$3.7 billion notional value) traded on September 28, 2026.
“Following the results of the Brazilian presidential election, clients turned to our BRL futures market to immediately manage their risk outside of Brazilian trading hours, driving all-time record volume,” said Paul Houston, Global Head of FX Products, CME Group. “Even before the onshore market opened, $2.5 billion in notional value had already traded, roughly three times the year-to-date ADV for BRL futures. With liquidity in all timezones and contracts denominated in USD, our markets are fast becoming the main venue for Brazilian real price discovery and trading outside of onshore hours, giving global participants the liquidity they need around the clock.”
In the first half of 2026, Mexican peso and Brazilian real futures and options saw a record combined average daily volume of $2.94 billion.
For more information on CME Group BRL futures, please visit https://www.cmegroup.com/articles/faqs/latam-fx-futures-frequently-asked-questions.html
As the world’s leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world’s leading central counterparty clearing providers, CME Clearing.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC (“S&P DJI”). “S&P®”, “S&P 500®”, “SPY®”, “SPX®”, US 500 and The 500 are trademarks of Standard & Poor’s Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.
CME-G
View original content to download multimedia:https://www.prnewswire.com/news-releases/cme-group-brazilian-real-futures-set-new-daily-volume-record-following-election-302920902.html
SOURCE CME Group
Technology
Vera Health Quietly Became One of the World’s Most Used Clinical Tools. Now It Has Raised $32 Million to Give Every Clinician in the World the Best Medical Knowledge in Seconds
Published
13 minutes agoon
October 27, 2026By
With a team of just 12 employees, the clinical AI company has grown largely through physician referrals, bringing total funding to $32 million
More than 800,000 clinicians across 190 countries use Vera Health, including approximately 1 in 4 physicians in Spain and Italy, with most discovering the platform through recommendations from colleagues.Threshold Ventures led Vera Health’s $28.5 million Series A, with participation from Mantis VC and SV Angel. Existing investors Y Combinator and Gradient tripled down, bringing total funding to $32 million.The investment will accelerate Vera Health’s evidence-focused clinical AI platform, expanding its ability to make global medical knowledge locally relevant and deepening partnerships with medical societies, publishers and health systems.
SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ — A year ago, a few thousand clinicians were using Vera Health. Today, more than 800,000 are, most having discovered the platform through a colleague. Every month since June, Vera has been the most downloaded clinical app in the world across the App Store and Google Play.¹ In September alone, it was downloaded more times than OpenEvidence and Doximity combined, while monthly downloads had more than tripled since February. With a team of just 12 employees, Vera has reached clinicians in 190 countries, including approximately 1 in 4 physicians in Spain and Italy, largely through word of mouth. Vera Health is a clinical AI search engine that reasons like a clinician, helping physicians find and evaluate medical evidence in seconds.
Today, Vera Health announced a $28.5 million Series A led by Threshold Ventures, with participation from Mantis VC and SV Angel. Existing investors Y Combinator and Gradient, tripled down in the round, bringing the company’s total funding to $32 million. The investment will accelerate Vera Health’s mission to close the gap between what medicine knows and what every patient receives.
Only a few months after raising its Series A, Vera already has more daily active users than it had monthly active users at the time of the raise. Clinicians went from asking Vera a few thousand questions a day to asking hundreds of thousands, every single day.
“Clinicians are the best data scientists I’ve ever met. They make the call in seconds, with more evidence than any human could ever read,” said Taieb Bennani, Co-Founder of Vera Health. “The secret to building for them is to live and breathe the problem like no one else. Everyone on our team is a clinician, or the child or sibling of one, like Maxime and me. That passion translates into every detail of the product, and when you build with that kind of obsession, the product speaks for itself, and clinicians share it with their colleagues. We don’t have the biggest team or the most money. We have the people who care the most about getting it right.”
How does Vera Health differ from general-purpose AI tools?
Clinical AI is increasingly being used to help physicians navigate complex medical questions, but the ability to generate an accurate-sounding answer does not necessarily establish whether the underlying research is reliable. Medicine now publishes a new scientific paper roughly every 20 seconds. Chatbots are built to sound confident. Vera is built to be accurate, and honest when the evidence is thin. Physicians are expected to keep up with an expanding body of research while interpreting guidelines, evaluating treatment options and making decisions for individual patients, sometimes within seconds.
Vera Health finds the evidence first, then writes the answer. Its technology searches more than 60 million peer-reviewed publications, clinical guidelines, consensus statements and drug labels, evaluating sources based on study design, level of evidence, cohort size, recency, journal quality and citation impact. Every claim is linked to its supporting research and color-coded to show the strength of the available evidence. Sometimes that color is red. A rare condition may have no large randomized trial or comprehensive guideline behind it, leaving only a small case series or a report involving a single patient. Vera Health surfaces that research while making its limitations visible, allowing physicians to assess how much weight the findings deserve.
“Medical knowledge moves too quickly for any one clinician to read, and general-purpose AI tools can make uncertain evidence sound settled,” said Maxime Allouch, co-founder, Vera Health. “Unlike other tools, we believe there’s value in making uncertainty visible. The grade shapes what Vera retrieves and writes, while the clinician brings the patient, the context and the judgment.”
Vera Health developed its approach alongside physicians who evaluate medical evidence and help write the guidelines other clinicians follow. Through its partnership with the American College of Emergency Physicians (ACEP), the platform integrates ACEP clinical policies with source attribution, bringing medical society guidance directly into clinical research workflows.
“In medicine, not all evidence is equal,” said Scott M. Silvers, MD, FACEP, Chair of the American College of Emergency Physicians’ Clinical Policies Committee and former Chair of Emergency Medicine at Mayo Clinic. “A large, randomized trial and a case report should never carry the same weight, yet most AI tools blend them into the same confident answer. Level of evidence is the foundation of every guideline we write, and Vera Health is built on it.”
For Dr. Bernard P. Chang, Vera Health’s Chief Scientific Advisor and Vice Chair of Research in the Department of Emergency Medicine at Columbia University, the importance of clinical evidence extends to how physicians evaluate patients.
“On a recent emergency-department shift, I saw a young woman with cough and shortness of breath. The symptoms could easily be attributed to a routine respiratory illness,” said Chang. “Vera Health surfaced evidence that raised my concern for pulmonary embolism, a potentially life-threatening blood clot in the lungs, and led me to broaden my evaluation. What interests me isn’t AI simply providing an answer. It’s whether it can reliably surface evidence that challenges our initial assumptions and improves clinical reasoning. That’s what we’re now evaluating rigorously, inside the academic medical centers where medicine is actually practiced.”
Vera Health’s clinical advisors also include Christopher Baugh, MD, MBA, FACEP, Vice Chair of Clinical Affairs in Emergency Medicine at Brigham and Women’s Hospital and Associate Professor of Emergency Medicine at Harvard Medical School. Its clinical council includes physician leaders affiliated with Mayo Clinic, Yale, Harvard, Columbia and Penn.
Why is Vera Health growing so quickly across international markets?
Bennani and Allouch grew up in families of physicians and initially developed Vera Health for their own fathers. What began with two users has since grown into a platform serving hundreds of thousands of clinicians, with physicians asking hundreds of thousands of questions each day. The company’s international growth reflects an approach built around a central reality of medicine. Medical knowledge is global, but clinical practice is local.
An emergency physician in France may follow different treatment guidelines than a physician in the United States. An oncologist reviewing a complex case may need an exhaustive evaluation of the available research, while an emergency physician needs a concise answer within seconds. Even physicians practicing the same specialty may follow different protocols depending on their institution.
Vera Health accounts for those differences by prioritizing locally relevant guidance while drawing on medical research from around the world. Through Vera Spaces, health systems can also integrate their own clinical protocols and pathways alongside national guidelines and international medical literature.
“Medicine is global, yet most tools in our space were built for a single geography,” said Allouch. “We went international from day one, because only a global view reveals what is truly local.”
The approach has helped Vera Health expand across Europe, where approximately 1 in 4 physicians in Spain and Italy and 1 in 7 in France use the platform, according to company data. Vera Health has achieved that international reach with a small team and a product that clinicians have largely discovered through their peers.
What will Vera Health’s Series A funding support next?
The financing will support further development of Vera Health’s clinical evidence infrastructure, expansion into additional healthcare markets and deeper partnerships with medical societies, publishers and health systems. The company will continue investing in locally relevant clinical guidance and tools that allow healthcare institutions to incorporate their own medical knowledge into the platform.
“In healthcare, trust is earned, not bought. Vera’s adoption among clinicians worldwide speaks to what Taieb and Maxime have built. By combining the most rigorous medical evidence with an understanding of each physician’s specialty, protocols and practice context, Vera makes the world’s medical knowledge relevant to how care is actually delivered. We believe that creates an enormous opportunity to improve global health,” said Andrew Brackin, Partner at Gradient.
“Vera is compelling because it starts with the evidence, not just an answer—helping clinicians find and assess the research behind a decision while making its strengths and limitations visible. By bringing that evidence to the point of care, Vera becomes a trusted clinical intelligence layer, not just another AI tool,” said Emily Melton, co-founder and managing partner of Threshold Ventures.
Vera Health will remain free for licensed clinicians and medical trainees worldwide as it expands access to medical evidence and locally relevant clinical guidance.
New medical knowledge takes an estimated 17 years to reach routine clinical practice, according to research published in the Journal of the Royal Society of Medicine. Vera Health aims to reduce the time physicians spend searching for and evaluating that knowledge, bringing relevant evidence closer to the moment clinical decisions are made.
“Our mission is to close the gap between what medicine knows and what every patient receives,” said Bennani. “Today, that gap is measured in years. We want it measured in seconds.”
About Vera Health
Vera Health is the search engine that reasons like a clinician, finding and grading evidence before showing the source, strength and limits behind every answer. More than 800,000 clinicians in 190 countries use Vera, which is free for licensed clinicians and trainees, never trains on clinicians’ questions, and is HIPAA and GDPR compliant and SOC 2 Type II certified. Founded in 2024 at Y Combinator by MIT graduates and sons of physicians Taieb Bennani and Maxime Allouch, Vera is headquartered in San Francisco and backed by Threshold Ventures, Gradient, Y Combinator, SV Angel and Mantis VC.
Learn more at verahealth.ai.
¹ Download data: Appark, worldwide App Store and Google Play downloads, June through [September] 2026.
Media Contact
Interdependence
(949) 259-6377 x 225
425709@email4pr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vera-health-quietly-became-one-of-the-worlds-most-used-clinical-tools-now-it-has-raised-32-million-to-give-every-clinician-in-the-world-the-best-medical-knowledge-in-seconds-302920905.html
SOURCE Vera Health
Vertical IQ Will Expand Industry Intelligence Platform with Small Business Financial Exchange (SBFE) Small Business Credit Data
CME Group Brazilian Real Futures Set New Daily Volume Record Following Election
Vera Health Quietly Became One of the World’s Most Used Clinical Tools. Now It Has Raised $32 Million to Give Every Clinician in the World the Best Medical Knowledge in Seconds
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days agoMiami Startup BOB Raises $5.5M To Build An AI-Powered Banking Platform
-
Coin Market4 days agoCysic dangles a 10% bounty, hacker pours loot into Tornado Cash
-
Coin Market4 days agoBitcoin ETFs bleed $635M as October slides back into the red
-
Coin Market4 days agoEthereum delays Glamsterdam Hoodi testnet launch over security risks
-
Coin Market4 days agoMalaysia, Thailand join Singapore’s cross-border stablecoin push
-
Technology4 days agoKin Becomes First U.S. Home Insurer to Enable WebMCP for AI Shopping
-
Coin Market5 days agoWinklevoss PAC moves into Texas Senate race with $81K ad buy
-
Technology5 days agoLunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister
